A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non–Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
There is an urgent and unmet need for more effective treatment options for patients with metastatic and recurrent non–small-cell lung cancer (NSCLC) who progressed on platinum-based therapy, immune checkpoint inhibitors (ICI), and targeted therapies. Currently, the combination of docetaxel (D) and r...
Saved in:
Published in | Clinical lung cancer Vol. 23; no. 7; pp. e400 - e404 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.11.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | There is an urgent and unmet need for more effective treatment options for patients with metastatic and recurrent non–small-cell lung cancer (NSCLC) who progressed on platinum-based therapy, immune checkpoint inhibitors (ICI), and targeted therapies. Currently, the combination of docetaxel (D) and ramucirumab (R) is the next best salvage therapy with a modest historical progression free survival (PFS) of 4.5 months and 6-month PFS rate of 37% predating the era of ICI use. Anecdotal reports in patients who progressed on ICI suggest a higher response rate to docetaxel compared to historical experience. Furthermore, tumor related angiogenesis promotes tumor growth and may contribute to immune escape in patients treated with ICI. Therapeutic combination with anti-angiogenic, ICI, and chemotherapy have independently demonstrated clinical efficacy without additive toxicities in NSCLC patients.
This multicenter, single arm, open label, phase 2 study will evaluate the safety and preliminary efficacy of the combination of docetaxel 75 mg/m2, ramucirumab 10 mg/kg, and pembrolizumab 200 mg in up to 41 patients with metastatic or recurrent NSCLC after progression on concomitant or sequential platinum-based chemotherapy and ICI. This treatment will be given intravenously on the same day every 3 weeks until disease progression, occurrence of severe side effects, or no clinical benefit. The primary endpoint is 6-month PFS rate.
This is the first study to evaluate the safety and efficacy of ICI combined with docetaxel and ramucirumab. The findings could provide valuable information for developing new treatment strategies for NSCLC patients. |
---|---|
AbstractList | There is an urgent and unmet need for more effective treatment options for patients with metastatic and recurrent non–small-cell lung cancer (NSCLC) who progressed on platinum-based therapy, immune checkpoint inhibitors (ICI), and targeted therapies. Currently, the combination of docetaxel (D) and ramucirumab (R) is the next best salvage therapy with a modest historical progression free survival (PFS) of 4.5 months and 6-month PFS rate of 37% predating the era of ICI use. Anecdotal reports in patients who progressed on ICI suggest a higher response rate to docetaxel compared to historical experience. Furthermore, tumor related angiogenesis promotes tumor growth and may contribute to immune escape in patients treated with ICI. Therapeutic combination with anti-angiogenic, ICI, and chemotherapy have independently demonstrated clinical efficacy without additive toxicities in NSCLC patients.
This multicenter, single arm, open label, phase 2 study will evaluate the safety and preliminary efficacy of the combination of docetaxel 75 mg/m2, ramucirumab 10 mg/kg, and pembrolizumab 200 mg in up to 41 patients with metastatic or recurrent NSCLC after progression on concomitant or sequential platinum-based chemotherapy and ICI. This treatment will be given intravenously on the same day every 3 weeks until disease progression, occurrence of severe side effects, or no clinical benefit. The primary endpoint is 6-month PFS rate.
This is the first study to evaluate the safety and efficacy of ICI combined with docetaxel and ramucirumab. The findings could provide valuable information for developing new treatment strategies for NSCLC patients. There is an urgent and unmet need for more effective treatment options for patients with metastatic and recurrent non-small-cell lung cancer (NSCLC) who progressed on platinum-based therapy, immune checkpoint inhibitors (ICI), and targeted therapies. Currently, the combination of docetaxel (D) and ramucirumab (R) is the next best salvage therapy with a modest historical progression free survival (PFS) of 4.5 months and 6-month PFS rate of 37% predating the era of ICI use. Anecdotal reports in patients who progressed on ICI suggest a higher response rate to docetaxel compared to historical experience. Furthermore, tumor related angiogenesis promotes tumor growth and may contribute to immune escape in patients treated with ICI. Therapeutic combination with anti-angiogenic, ICI, and chemotherapy have independently demonstrated clinical efficacy without additive toxicities in NSCLC patients. This multicenter, single arm, open label, phase 2 study will evaluate the safety and preliminary efficacy of the combination of docetaxel 75 mg/m , ramucirumab 10 mg/kg, and pembrolizumab 200 mg in up to 41 patients with metastatic or recurrent NSCLC after progression on concomitant or sequential platinum-based chemotherapy and ICI. This treatment will be given intravenously on the same day every 3 weeks until disease progression, occurrence of severe side effects, or no clinical benefit. The primary endpoint is 6-month PFS rate. This is the first study to evaluate the safety and efficacy of ICI combined with docetaxel and ramucirumab. The findings could provide valuable information for developing new treatment strategies for NSCLC patients. |
Author | Owonikoko, Taofeek Pakkala, Suchita Osta, Badi El Liu, Yuan Leal, Ticiana Carlisle, Jennifer Dhodapkar, Madhav Ramalingam, Suresh Chen, Zhengjia Steuer, Conor |
Author_xml | – sequence: 1 givenname: Badi El orcidid: 0000-0002-9905-0897 surname: Osta fullname: Osta, Badi El email: belosta@emory.edu organization: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA – sequence: 2 givenname: Jennifer surname: Carlisle fullname: Carlisle, Jennifer organization: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA – sequence: 3 givenname: Conor surname: Steuer fullname: Steuer, Conor organization: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA – sequence: 4 givenname: Suchita surname: Pakkala fullname: Pakkala, Suchita organization: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA – sequence: 5 givenname: Ticiana surname: Leal fullname: Leal, Ticiana organization: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA – sequence: 6 givenname: Madhav surname: Dhodapkar fullname: Dhodapkar, Madhav organization: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA – sequence: 7 givenname: Yuan surname: Liu fullname: Liu, Yuan organization: Winship Cancer Institute of Emory University, Atlanta, GA – sequence: 8 givenname: Zhengjia surname: Chen fullname: Chen, Zhengjia organization: Division of Epidemiology and Biostatistics, University of Illinois Cancer Center, Chicago, IL – sequence: 9 givenname: Taofeek surname: Owonikoko fullname: Owonikoko, Taofeek organization: Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA – sequence: 10 givenname: Suresh surname: Ramalingam fullname: Ramalingam, Suresh organization: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35863963$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u1DAQxy1URD_gBTigOYLUpP7YmETiUrLlQwpl1QVxjBx73M3ixJWdQMuJd-CdeBCeBK8WOHKZGc3M_6_R_I7JwehHJOQxozmjTJ5tc-2czjnlPKcyp1TcI0esEmVGZUUPUl3wInsu6OKQHMe4pZRLwfgDciiKUopKiiPy8xxWGxUROKyn2dyBt7D0Gid1i-4UrtQw6z7Mg-pOQY0GVjh0wbv-264F1gdYqanHcYrwqZ828C4p45RaGtLsCvUcQprCpR9_ff-xHpRzWY3OQTOP11CrUWOAp5fruqmfwdeNh1Xw1wFjRAN-hJVLVuM8ZEs_dw6n_Q3LjJ2l0DB46bz-rAw-JPetchEf_ckn5OOriw_1m6x5__ptfd5kmpdyykqjRGEoW_CikLIqNNqOdhIlV5VlShrLOxTSCs4qWzCrS7qgtKyqoliUldbihPC9rw4-xoC2vQn9oMJdy2i7g9Ju2x2UdgelpbJNUJLoyV50M3cDmn-SvxTSwov9AqbTv_QY2qjTTzWaPqCeWuP7__n_Bj8poJY |
CitedBy_id | crossref_primary_10_1016_j_intimp_2023_110785 crossref_primary_10_1186_s12885_022_10045_0 crossref_primary_10_3389_fimmu_2023_1202822 crossref_primary_10_1016_j_intimp_2023_110214 |
Cites_doi | 10.1200/JCO.19.03158 10.1007/s11912-000-0016-x 10.1056/NEJMoa1801005 10.1080/2162402X.2019.1665974 10.1016/S0140-6736(15)01281-7 10.3389/fimmu.2021.689132 10.1016/S0140-6736(21)00228-2 10.1016/S0140-6736(14)60845-X 10.1200/JCO.19.03136 10.1016/S1470-2045(20)30641-0 10.1056/NEJMoa1504627 10.1016/S1470-2045(19)30458-9 10.1056/NEJMoa1810865 10.1016/S2213-2600(19)30084-0 10.1016/j.annonc.2021.04.008 10.1016/j.jtho.2020.10.004 10.1056/NEJMoa1917346 10.1056/NEJMoa1716948 10.1001/jamanetworkopen.2020.11809 10.1200/JCO.22.01035 10.1200/JCO.19.01348 10.1016/j.lungcan.2017.07.034 10.1001/jamaoncol.2020.0409 10.1016/j.ejca.2019.05.008 10.1056/NEJMoa1606774 10.1200/JCO.18.00149 10.1016/S0140-6736(16)32517-X |
ContentType | Journal Article |
Copyright | 2022 Copyright © 2022. Published by Elsevier Inc. |
Copyright_xml | – notice: 2022 – notice: Copyright © 2022. Published by Elsevier Inc. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1016/j.cllc.2022.06.003 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1938-0690 |
EndPage | e404 |
ExternalDocumentID | 10_1016_j_cllc_2022_06_003 35863963 S1525730422001474 |
Genre | Multicenter Study Clinical Trial, Phase II Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA138292 |
GroupedDBID | --- --K --M .1- .FO .XZ .~1 0R~ 1P~ 1~. 29B 4.4 457 4G. 53G 5GY 5VS 6J9 6PF 7-5 8P~ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXUO ABBQC ABFNM ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEGXH AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF DU5 EBS EFJIC EFLBG EJD EMB EMOBN F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM LCYCR M41 MET MO0 O-L O9- OAUVE OBH OC~ OHH OO- OVD P-8 P-9 PC. Q38 R2- ROL SDF SEL SES SPCBC SSH SSZ SV3 T5K TEORI UDS Z5R ~G- AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-c286t-8da35d0142556695cefb0b6e62a9f1a6df2be36f3219f51fc8040089955489cc3 |
IEDL.DBID | .~1 |
ISSN | 1525-7304 |
IngestDate | Thu Sep 26 18:13:28 EDT 2024 Sat Sep 28 08:16:47 EDT 2024 Fri Feb 23 02:40:20 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | Chemotherapy Phase 2 Anti-angiogenic Immunotherapy Non-small cell lung cancer |
Language | English |
License | Copyright © 2022. Published by Elsevier Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c286t-8da35d0142556695cefb0b6e62a9f1a6df2be36f3219f51fc8040089955489cc3 |
ORCID | 0000-0002-9905-0897 |
PMID | 35863963 |
ParticipantIDs | crossref_primary_10_1016_j_cllc_2022_06_003 pubmed_primary_35863963 elsevier_sciencedirect_doi_10_1016_j_cllc_2022_06_003 |
PublicationCentury | 2000 |
PublicationDate | November 2022 2022-11-00 |
PublicationDateYYYYMMDD | 2022-11-01 |
PublicationDate_xml | – month: 11 year: 2022 text: November 2022 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical lung cancer |
PublicationTitleAlternate | Clin Lung Cancer |
PublicationYear | 2022 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Reck, Rodriguez-Abreu, Robinson (bib0001) 2016; 375 Rodriguez-Abreu, Powell, Hochmair (bib0011) 2021; 32 Socinski, Jotte, Cappuzzo (bib0013) 2018; 378 Reck, Rodriguez-Abreu, Robinson (bib0002) 2019; 37 Ren, Xiong, You, Shen, Zhou (bib0020) 2021; 12 Reck, Wehler, Orlandi (bib0022) 2020; 38 Rittmeyer, Barlesi, Waterkamp (bib0006) 2017; 389 Paz-Ares, Luft, Vicente (bib0010) 2018; 379 Herbst, Arkenau, Santana-Davila (bib0026) 2019; 20 El-Osta, Mott, Burt, Wang, Sabichi (bib0016) 2019; 8 Sezer, Kilickap, Gumus (bib0008) 2021; 397 Schvartsman, Peng, Bis (bib0025) 2017; 112 Arrieta, Barron, Ramirez-Tirado (bib0024) 2020; 6 Paz-Ares, Ciuleanu, Cobo (bib0014) 2021; 22 Gandhi, Rodriguez-Abreu, Gadgeel (bib0012) 2018; 378 Reckamp, Redman, Dragnev (bib28) 2022 Brahmer, Reckamp, Baas (bib0005) 2015; 373 Garon, Ciuleanu, Arrieta (bib0018) 2014; 384 Reck, Mok, Nishio (bib0015) 2019; 7 Daum, Hagen, Naismith, Wolf, Pircher (bib0021) 2020; 8 Kok, Cho, Yoon (bib0027) 2020; 3 Reck, Schenker, Lee (bib0003) 2019; 116 Herbst, Giaccone, de Marinis (bib0007) 2020; 383 Herbst, Arkenau, Bendell (bib0023) 2021; 16 Mazieres, Kowalski, Luft (bib0017) 2020; 38 Fossella (bib0019) 2000; 2 Herbst, Baas, Kim (bib0004) 2016; 387 Gadgeel, Rodriguez-Abreu, Speranza (bib0009) 2020; 38 Leal, Dahlberg, Ramalingam (bib29) 2022 Herbst (10.1016/j.cllc.2022.06.003_bib0004) 2016; 387 Garon (10.1016/j.cllc.2022.06.003_bib0018) 2014; 384 Schvartsman (10.1016/j.cllc.2022.06.003_bib0025) 2017; 112 El-Osta (10.1016/j.cllc.2022.06.003_bib0016) 2019; 8 Reck (10.1016/j.cllc.2022.06.003_bib0001) 2016; 375 Reck (10.1016/j.cllc.2022.06.003_bib0015) 2019; 7 Herbst (10.1016/j.cllc.2022.06.003_bib0023) 2021; 16 Fossella (10.1016/j.cllc.2022.06.003_bib0019) 2000; 2 Daum (10.1016/j.cllc.2022.06.003_bib0021) 2020; 8 Rodriguez-Abreu (10.1016/j.cllc.2022.06.003_bib0011) 2021; 32 Gandhi (10.1016/j.cllc.2022.06.003_bib0012) 2018; 378 Mazieres (10.1016/j.cllc.2022.06.003_bib0017) 2020; 38 Herbst (10.1016/j.cllc.2022.06.003_bib0026) 2019; 20 Arrieta (10.1016/j.cllc.2022.06.003_bib0024) 2020; 6 Sezer (10.1016/j.cllc.2022.06.003_bib0008) 2021; 397 Ren (10.1016/j.cllc.2022.06.003_bib0020) 2021; 12 Leal (10.1016/j.cllc.2022.06.003_bib29) 2022 Kok (10.1016/j.cllc.2022.06.003_bib0027) 2020; 3 Herbst (10.1016/j.cllc.2022.06.003_bib0007) 2020; 383 Socinski (10.1016/j.cllc.2022.06.003_bib0013) 2018; 378 Reck (10.1016/j.cllc.2022.06.003_bib0022) 2020; 38 Rittmeyer (10.1016/j.cllc.2022.06.003_bib0006) 2017; 389 Reckamp (10.1016/j.cllc.2022.06.003_bib28) 2022 Reck (10.1016/j.cllc.2022.06.003_bib0003) 2019; 116 Gadgeel (10.1016/j.cllc.2022.06.003_bib0009) 2020; 38 Reck (10.1016/j.cllc.2022.06.003_bib0002) 2019; 37 Paz-Ares (10.1016/j.cllc.2022.06.003_bib0014) 2021; 22 Paz-Ares (10.1016/j.cllc.2022.06.003_bib0010) 2018; 379 Brahmer (10.1016/j.cllc.2022.06.003_bib0005) 2015; 373 |
References_xml | – volume: 387 start-page: 1540 year: 2016 end-page: 1550 ident: bib0004 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet contributor: fullname: Kim – volume: 383 start-page: 1328 year: 2020 end-page: 1339 ident: bib0007 article-title: Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC publication-title: N Engl J Med contributor: fullname: de Marinis – volume: 7 start-page: 387 year: 2019 end-page: 401 ident: bib0015 article-title: Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial publication-title: Lancet Respir Med contributor: fullname: Nishio – volume: 397 start-page: 592 year: 2021 end-page: 604 ident: bib0008 article-title: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial publication-title: Lancet contributor: fullname: Gumus – volume: 20 start-page: 1109 year: 2019 end-page: 1123 ident: bib0026 article-title: Ramucirumab plus pembrolizumab in patients with previously treated advanced non–small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial publication-title: Lancet Oncol contributor: fullname: Santana-Davila – volume: 38 start-page: 271 year: 2020 end-page: 280 ident: bib0017 article-title: Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non–small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: Luft – volume: 6 start-page: 856 year: 2020 end-page: 864 ident: bib0024 article-title: Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non–small cell lung cancer: the PROLUNG phase 2 randomized clinical trial publication-title: JAMA Oncol contributor: fullname: Ramirez-Tirado – volume: 8 year: 2020 ident: bib0021 article-title: The role of anti-angiogenesis in the treatment landscape of non–small cell lung cancer—new combinational approaches and strategies of neovessel inhibition publication-title: Front Cell Dev Biol contributor: fullname: Pircher – volume: 37 start-page: 537 year: 2019 end-page: 546 ident: bib0002 article-title: Updated Analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater publication-title: J Clin Oncol contributor: fullname: Robinson – volume: 12 year: 2021 ident: bib0020 article-title: The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non–small-cell lung cancer publication-title: Front Immunol contributor: fullname: Zhou – volume: 2 start-page: 96 year: 2000 end-page: 101 ident: bib0019 article-title: Second-line chemotherapy for non–small-cell lung cancer publication-title: Curr Oncol Rep contributor: fullname: Fossella – volume: 16 start-page: 289 year: 2021 end-page: 298 ident: bib0023 article-title: Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC publication-title: J Thorac Oncol contributor: fullname: Bendell – year: 2022 ident: bib28 article-title: Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A publication-title: J Clin Oncol contributor: fullname: Dragnev – volume: 378 start-page: 2078 year: 2018 end-page: 2092 ident: bib0012 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Gadgeel – volume: 389 start-page: 255 year: 2017 end-page: 265 ident: bib0006 article-title: Atezolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet contributor: fullname: Waterkamp – volume: 379 start-page: 2040 year: 2018 end-page: 2051 ident: bib0010 article-title: Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Vicente – volume: 373 start-page: 123 year: 2015 end-page: 135 ident: bib0005 article-title: Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Baas – volume: 32 start-page: 881 year: 2021 end-page: 895 ident: bib0011 article-title: Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 publication-title: Ann Oncol contributor: fullname: Hochmair – year: 2022 ident: bib29 article-title: Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes publication-title: J Clin Oncol contributor: fullname: Ramalingam – volume: 38 start-page: 2530 year: 2020 end-page: 2542 ident: bib0022 article-title: Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non–small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: Orlandi – volume: 3 year: 2020 ident: bib0027 article-title: Validation of progression-free survival rate at 6 months and objective response for estimating overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis publication-title: JAMA Netw Open contributor: fullname: Yoon – volume: 38 start-page: 1505 year: 2020 end-page: 1517 ident: bib0009 article-title: Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: Speranza – volume: 8 year: 2019 ident: bib0016 article-title: Predictors of benefits from frontline chemoimmunotherapy in stage IV non–small-cell lung cancer: a meta-analysis publication-title: Oncoimmunology contributor: fullname: Sabichi – volume: 384 start-page: 665 year: 2014 end-page: 673 ident: bib0018 article-title: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non–small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial publication-title: Lancet contributor: fullname: Arrieta – volume: 375 start-page: 1823 year: 2016 end-page: 1833 ident: bib0001 article-title: Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer publication-title: N Engl J Med contributor: fullname: Robinson – volume: 116 start-page: 137 year: 2019 end-page: 147 ident: bib0003 article-title: Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial publication-title: Eur J Cancer contributor: fullname: Lee – volume: 112 start-page: 90 year: 2017 end-page: 95 ident: bib0025 article-title: Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non–small-cell lung cancer publication-title: Lung Cancer contributor: fullname: Bis – volume: 378 start-page: 2288 year: 2018 end-page: 2301 ident: bib0013 article-title: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC publication-title: N Engl J Med contributor: fullname: Cappuzzo – volume: 22 start-page: 198 year: 2021 end-page: 211 ident: bib0014 article-title: First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial publication-title: Lancet Oncol contributor: fullname: Cobo – volume: 38 start-page: 2530 year: 2020 ident: 10.1016/j.cllc.2022.06.003_bib0022 article-title: Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non–small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.19.03158 contributor: fullname: Reck – volume: 2 start-page: 96 year: 2000 ident: 10.1016/j.cllc.2022.06.003_bib0019 article-title: Second-line chemotherapy for non–small-cell lung cancer publication-title: Curr Oncol Rep doi: 10.1007/s11912-000-0016-x contributor: fullname: Fossella – volume: 378 start-page: 2078 year: 2018 ident: 10.1016/j.cllc.2022.06.003_bib0012 article-title: Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1801005 contributor: fullname: Gandhi – volume: 8 year: 2019 ident: 10.1016/j.cllc.2022.06.003_bib0016 article-title: Predictors of benefits from frontline chemoimmunotherapy in stage IV non–small-cell lung cancer: a meta-analysis publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1665974 contributor: fullname: El-Osta – volume: 387 start-page: 1540 year: 2016 ident: 10.1016/j.cllc.2022.06.003_bib0004 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01281-7 contributor: fullname: Herbst – volume: 12 year: 2021 ident: 10.1016/j.cllc.2022.06.003_bib0020 article-title: The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non–small-cell lung cancer publication-title: Front Immunol doi: 10.3389/fimmu.2021.689132 contributor: fullname: Ren – volume: 397 start-page: 592 year: 2021 ident: 10.1016/j.cllc.2022.06.003_bib0008 article-title: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(21)00228-2 contributor: fullname: Sezer – volume: 384 start-page: 665 year: 2014 ident: 10.1016/j.cllc.2022.06.003_bib0018 article-title: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non–small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(14)60845-X contributor: fullname: Garon – year: 2022 ident: 10.1016/j.cllc.2022.06.003_bib28 article-title: Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A publication-title: J Clin Oncol contributor: fullname: Reckamp – volume: 38 start-page: 1505 year: 2020 ident: 10.1016/j.cllc.2022.06.003_bib0009 article-title: Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.19.03136 contributor: fullname: Gadgeel – volume: 22 start-page: 198 year: 2021 ident: 10.1016/j.cllc.2022.06.003_bib0014 article-title: First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30641-0 contributor: fullname: Paz-Ares – volume: 373 start-page: 123 year: 2015 ident: 10.1016/j.cllc.2022.06.003_bib0005 article-title: Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1504627 contributor: fullname: Brahmer – volume: 20 start-page: 1109 year: 2019 ident: 10.1016/j.cllc.2022.06.003_bib0026 article-title: Ramucirumab plus pembrolizumab in patients with previously treated advanced non–small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30458-9 contributor: fullname: Herbst – volume: 379 start-page: 2040 year: 2018 ident: 10.1016/j.cllc.2022.06.003_bib0010 article-title: Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1810865 contributor: fullname: Paz-Ares – volume: 7 start-page: 387 year: 2019 ident: 10.1016/j.cllc.2022.06.003_bib0015 article-title: Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(19)30084-0 contributor: fullname: Reck – volume: 32 start-page: 881 year: 2021 ident: 10.1016/j.cllc.2022.06.003_bib0011 article-title: Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 publication-title: Ann Oncol doi: 10.1016/j.annonc.2021.04.008 contributor: fullname: Rodriguez-Abreu – volume: 16 start-page: 289 year: 2021 ident: 10.1016/j.cllc.2022.06.003_bib0023 article-title: Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2020.10.004 contributor: fullname: Herbst – volume: 383 start-page: 1328 year: 2020 ident: 10.1016/j.cllc.2022.06.003_bib0007 article-title: Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC publication-title: N Engl J Med doi: 10.1056/NEJMoa1917346 contributor: fullname: Herbst – volume: 378 start-page: 2288 year: 2018 ident: 10.1016/j.cllc.2022.06.003_bib0013 article-title: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC publication-title: N Engl J Med doi: 10.1056/NEJMoa1716948 contributor: fullname: Socinski – volume: 3 year: 2020 ident: 10.1016/j.cllc.2022.06.003_bib0027 article-title: Validation of progression-free survival rate at 6 months and objective response for estimating overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.11809 contributor: fullname: Kok – year: 2022 ident: 10.1016/j.cllc.2022.06.003_bib29 article-title: Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes publication-title: J Clin Oncol doi: 10.1200/JCO.22.01035 contributor: fullname: Leal – volume: 38 start-page: 271 year: 2020 ident: 10.1016/j.cllc.2022.06.003_bib0017 article-title: Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non–small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.19.01348 contributor: fullname: Mazieres – volume: 112 start-page: 90 year: 2017 ident: 10.1016/j.cllc.2022.06.003_bib0025 article-title: Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non–small-cell lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2017.07.034 contributor: fullname: Schvartsman – volume: 6 start-page: 856 year: 2020 ident: 10.1016/j.cllc.2022.06.003_bib0024 article-title: Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non–small cell lung cancer: the PROLUNG phase 2 randomized clinical trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2020.0409 contributor: fullname: Arrieta – volume: 116 start-page: 137 year: 2019 ident: 10.1016/j.cllc.2022.06.003_bib0003 article-title: Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial publication-title: Eur J Cancer doi: 10.1016/j.ejca.2019.05.008 contributor: fullname: Reck – volume: 8 year: 2020 ident: 10.1016/j.cllc.2022.06.003_bib0021 article-title: The role of anti-angiogenesis in the treatment landscape of non–small cell lung cancer—new combinational approaches and strategies of neovessel inhibition publication-title: Front Cell Dev Biol contributor: fullname: Daum – volume: 375 start-page: 1823 year: 2016 ident: 10.1016/j.cllc.2022.06.003_bib0001 article-title: Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1606774 contributor: fullname: Reck – volume: 37 start-page: 537 year: 2019 ident: 10.1016/j.cllc.2022.06.003_bib0002 article-title: Updated Analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater publication-title: J Clin Oncol doi: 10.1200/JCO.18.00149 contributor: fullname: Reck – volume: 389 start-page: 255 year: 2017 ident: 10.1016/j.cllc.2022.06.003_bib0006 article-title: Atezolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32517-X contributor: fullname: Rittmeyer |
SSID | ssj0026312 |
Score | 2.3499274 |
Snippet | There is an urgent and unmet need for more effective treatment options for patients with metastatic and recurrent non–small-cell lung cancer (NSCLC) who... There is an urgent and unmet need for more effective treatment options for patients with metastatic and recurrent non-small-cell lung cancer (NSCLC) who... |
SourceID | crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | e400 |
SubjectTerms | Anti-angiogenic Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy Docetaxel - therapeutic use Humans Immune Checkpoint Inhibitors Immunotherapy Lung Neoplasms - pathology Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - etiology Non-small cell lung cancer Phase 2 Platinum - therapeutic use Programmed Cell Death 1 Receptor Ramucirumab |
Title | A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non–Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade |
URI | https://dx.doi.org/10.1016/j.cllc.2022.06.003 https://www.ncbi.nlm.nih.gov/pubmed/35863963 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZWi4S4IN4sj9UcOIDY0NaJ3eRYAqtCH6paVru3yHZsNUseq5KKxwHxH_hP_BB-CTNNsoIDHLgkihMnlmc03zj-ZoaxJzaSJoq08BS3gRdYF3ra4sLVcTsMg1QIbWihOJvL8Unw9kyc7bG4i4UhWmVr-xubvrPWbUuvnc3eRZb1VlS5Z0ircaIFBUPKCRogGKFOv_h6SfPg0m92PAWVbcWn28CZhuNl8pzSGHK-y-HZFc76Kzj9hjzHN9j11mWEUTOqm2zPlrfY1Vm7KX6b_RjBYo1gBByIFfgZKgeIHbZWn2x-BEtVbE222RZKH4EqU1jYQlOtni_UBOi0wqJJrvoBTrN6DTPsSXFGmQG8t6Qf8pTCCeZV-fPb91Wh8tyLbZ7DFA0FxKQ2G3g6X8XT-Bl8XFewIM4X5SRPoSphQWy7clt46Ktr1JJmDK-8QQ8P0wG8RDh9r1J7h50cv34Xj722PINneChrL0yVL1KcespiJiNhrNN9La3kKnIDJVPHtfWl89EoOjFwJiSDges79GDCyBj_Ltsvq9LeZxAhVPe5RoOnRKDR8OmhbyT2cgG6p7x_wJ53ckkumiwcSUdPO09IiglJMdlx9PwDJjrRJX_oUoIw8c9-9xo5X37DFyF6cNJ_8J9vfMiu0VUTu_iI7debrX2MTkytD3daesiujN5MxnM6T5ank1_cv_Ho |
link.rule.ids | 315,786,790,4521,24144,27957,27958,45620,45714 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbKVgIuiGcpzzlwANFoNw87yXEJVFuajVbdVvQW2Y6jDeRRLVnxOPEf-E_8EH4JM5ukggMcuORgaxLLY30zE38zw9gzEwodhopb0jGe5Zk8sJTBwDV3jB94GedKU6A4T8TszHt7zs93WDTkwhCtssf-DtO3aN2PjPvdHF8UxXhJnXt8isaJFuT53hW263Hf9kZsd3p0PEsu4y7hdpeenDq3okCfO9PRvHRZUiVDx9mW8Rx6Z_3VPv1mfA5vshu91wjTbmG32I6pb7Or8_5e_A77MYXFCu0ROEDEwC_Q5IDmw7TysykP4ERWG12sN5VUByDrDBamUtSu5ysNAfqtsOjqq36Ed0W7gjlKUqpRoQHnTuifPFVxgqSpf377vqxkWVqRKUuIESsgopOzhufJMoqjF_Bp1cCCaF9UljyDpoYFEe7qTWWhu67woHRreG3ZY3zENrxCi_pBZuYuOzt8cxrNrL5Dg6WdQLRWkEmXZ7j7VMhMhFybXE2UMMKRYW5LkeWOMq7IXcTFnNu5DggzMMRDJyYItXbvsVHd1OY-gxCt9cRRiHmSewqxT_muFiiVe-ihOpN99nLQS3rRFeJIB4ba-5S0mJIW0y1Nz91nfFBd-sdxStFS_FNur9Pz5TdcHqATJ9wH__nGp-za7HQep_FRcvyQXaeZLpXxERu16415jD5Nq570Z_YXo8by-w |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Phase+2+Study+of+Docetaxel%2C+Ramucirumab%2C+and+Pembrolizumab+for+Patients+With+Metastatic+or+Recurrent+Non%E2%80%93Small-Cell+Lung+Cancer+%28NSCLC%29+who+Progressed+on+Platinum-Doublet+and+PD-1%2FPD-L1+Blockade&rft.jtitle=Clinical+lung+cancer&rft.au=Osta%2C+Badi+El&rft.au=Carlisle%2C+Jennifer&rft.au=Steuer%2C+Conor&rft.au=Pakkala%2C+Suchita&rft.date=2022-11-01&rft.pub=Elsevier+Inc&rft.issn=1525-7304&rft.eissn=1938-0690&rft.volume=23&rft.issue=7&rft.spage=e400&rft.epage=e404&rft_id=info:doi/10.1016%2Fj.cllc.2022.06.003&rft.externalDocID=S1525730422001474 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1525-7304&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1525-7304&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1525-7304&client=summon |